Oncology News

The gut microbiome has become a focused topic for researchers lately in hepatology and gastroenterology as its effects on gastric and liver health have yet to be fully understood. ecent studies have metabolites and phyla organizations that incrase the risk for certain liver diseases or may protect from conditions such as nonalcoholic fatty livr disease.

The phase 3 REACH-2 trial of ramucirumab met its primary endpoint of OS and its secondary endpoint of PFS for the second-line treatment of patients with hepatocellular carcinoma with high alpha-fetoprotein, according to the agent’s manufacturer.

Patients with hepatitis B are at risk for infection-related cancer, and certain clinical factors play a part in the odds for relapse following therapy. Recent studies have focused on identifying patient characteristics and clinical factors that might predict disease progression, likelihood of seroclearance and risk for relapse.

Patients with alcohol-related hepatocellular carcinoma appeared to have worse prognosis than those with nonalcohol-related disease, according to study findings published in Cancer.

While hepatitis C screening improved recently, the increased rates are minimal and less than optimal among black individuals, Hispanics and women, according to a recently published study.

Diet and lifestyle play a large role in liver health. Lately, researchers have made several important discoveries regarding the ties between diet and the gut microbiome, and identified specific dietary components that either have protective qualities for liver health or increase the risk for liver disease and cancer.

Researchers developed a predictive risk score for the development hepatocellular carcinoma during oral antiviral therapy in patients with chronic hepatitis B, according to recently published data.

Talimogene laherparevec, a genetically modified version of the herpes virus, was well-tolerated after injection into active cancer in the liver and stimulated patient immune systems to destroy cancer cells throughout the body, according to a press release and presentation at the Society of Interventional Radiology Annual Scientific Meeting.

Researchers have developed a predictive score that quantifies the potential benefits of direct-acting antiviral therapy for patients with hepatitis C and decompensated cirrhosis, according to recently published data.

Exelixis submitted a supplemental new drug application to the FDA for Cabometyx tablets as a treatment for patients with previously treated advanced hepatocellular carcinoma based on positive results from a phase 3 trial, according to a press release.